This week, PAGB published a new report for our members which provides an in-depth analysis of the reclassification landscape for over-the-counter (OTC) medicines in the UK, following the Department of Health and Social Care (DHSC) announcement in early 2025.

Drawing upon insights from PAGB member companies, it highlights both the strategic significance and the operational challenges of reclassification as a business initiative. The findings reveal that reclassification is increasingly viewed as a cross-functional opportunity, requiring close collaboration across regulatory, commercial, and scientific teams.

The report recommends practical solutions and strategic recommendations essential to unlocking further innovation and growth in the consumer healthcare sector, supporting the aims of the NHS 10 Year Health Plan, and ultimately improving patient access to safe and effective self-care options.

The report can be viewed here.